Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

12.5%

2 terminated out of 16 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed with results

Key Signals

5 with results71% success

Data Visualizations

Phase Distribution

16Total
P 1 (8)
P 2 (8)

Trial Status

Completed5
Recruiting4
Active Not Recruiting4
Terminated2
Withdrawn1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT04200443Phase 2Active Not Recruiting

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

NCT05836571Phase 2Active Not Recruiting

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

NCT04028063Phase 2Active Not RecruitingPrimary

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

NCT06498648Phase 1Recruiting

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

NCT03793361Phase 2CompletedPrimary

Phase II Study of Regorafenib as Maintenance Therapy

NCT03965234Phase 1Recruiting

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

NCT06797999Phase 1RecruitingPrimary

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

NCT05075993Phase 1Active Not Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT03660930Phase 1Terminated

Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

NCT03138161Phase 1Recruiting

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

NCT01514188Phase 2CompletedPrimary

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

NCT03670069Phase 1Terminated

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

NCT02500797Phase 2Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

NCT03009201Phase 1Completed

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

NCT03397186Phase 2Withdrawn

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

NCT01574716Phase 2CompletedPrimary

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Showing all 16 trials

Research Network

Activity Timeline